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Purpose: To develop a reliable prognostic model for patients 
with metastatic renal cell carcinoma (RCC) based on features 
readily available in common clinical settings. Patients and 
Methods: A total of 197 patients with RCC who underwent 
nephrectomy and immunotherapy from 1995 to 2004 were 
retrospectively reviewed. Their mean age was 55.1 ± 11.8 yrs 
(24 - 83 yrs) and mean survival time from metastasis was 22.6 
± 20.2 mos (3 - 120 mos). The impact of 24 clinicopathological 
features on disease specific survival was investigated. Results: 
On univariate analysis, constitutional symptoms, sarcomatoid 
differentiation, tumor necrosis, multiple primary lesions, liver 
metastasis, Eastern Cooperative Oncology Group Performance 
Status (ECOG-PS), thrombocytosis, alkaline phosphatase, 
hematocrit, T stage, N stage, and nuclear grade had significant 
influence on survival (p < 0.05). Multivariate analysis revealed 
the following features associated with survival: sarcomatoid 
differentiation [hazard ratio (HR) = 2.99, p < 0.001], liver 
metastasis (HR = 2.09, p = 0.002), ECOG-PS (HR = 1.95, p = 
0.005), N stage (HR = 1.94, p = 0.002), and number of 
metastatic sites (HR = 1.76, p = 0.003). An individual prognostic 
score was defined as the sum of the weight of these features. 
According to prognostic scores, patients could be subdivided 
into 3 groups: low risk (score 0), intermediate risk (score 1 
or 2), and high risk (score ≥ 3). Conclusion: A comprehensive 
prognostic stratification model was developed to predict 
survival and stratify patients for prospective clinical trials.
Key Words: Carcinoma, renal cell, neoplasm metastasis, 
nephrectomy, immunotherapy, prognosis
INTRODUCTION
If untreated, the prognosis for patients with 
metastatic renal cell carcinoma (RCC) is 
generally poor, with an overall median survival 
time of no more than 12 mos and a 5-yr survival 
rate of less than 10%.1 However, it is not easy to 
predict the individual prognosis of these patients 
since the natural history of RCC is complex and 
influenced by various patient- and tumor-related 
factors.2
Combination therapies of nephrectomy and 
immunotherapy for patients with metastatic RCC 
demonstrate only limited benefits.3,4 Recently, 
novel molecular-targeted agents showed a 
significant benefit on progression-free survival in 
patients for whom cytokine therapy had failed.5 
A variety of important prognostic indicators in 
metastatic RCC have previously been identified, 
and several prognosis prediction models have 
been suggested.6-12 These models can be used to 
counsel patients, determine the need for 
adjuvant therapy, stratify patients for clinical 
trials, and develop appropriate postoperative 
surveillance programs to monitor the risk of 
cancer progression.
In this study, a readily available comprehen-
sive model that is capable of predicting survival 
of patients with metastatic RCC who underwent 
radical nephrectomy and immunotherapy in 
common clinical settings was developed.
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Table 1. Patient Characteristics
Characteristics No. of patients (%)
Gender Male vs. Female  152 (77.2) vs. 45 (22.7)
Age (yrs)  < 60 vs. ≥ 60  120 (60.9) vs. 77 (39.1)
Constitutional symptoms Presence vs. Absence    79 (40.1) vs. 118 (59.9)
Local symptoms Presence vs. Absence    89 (45.2) vs. 108 (54.8)
Laterality Right vs. Left vs. Bilateral 93 (47.2) vs. 102 (51.8) vs. 2 (1.0)
T stage        T1 - 3 vs. T4 177 (89.8) vs 20 (10.2)
Size (cm) < 7 vs. ≧ 7    77 (39.1) vs. 120 (60.9)
Nuclear grade   Grade 1 - 3 vs. Grade 4  147 (74.6) vs. 50 (25.4)
Sarcomatoid differentiation Presence vs. Absence     18 (9.1) vs. 179 (90.9)
Tumor necrosis Presence vs. Absence   78 (39.6) vs 119 (60.4)
N stage pNx or pN0 vs. pN1 or pN2  163 (82.7) vs. 34 (17.3)
ECOG-PS 0, 1 vs. 2 - 4 177 (89.8) vs 20 (10.2)
Hematocrit (%)  < 40 vs. ≥ 40  138 (70.1) vs. 59 (29.9)
Platelet count (/mm3)  < 450,000 vs. ≥ 450,000 175 (90.9) vs. 22 (9.1)
Alkaline phosphatase (U/L)  < 110 vs. ≥ 110  138 (70.1) vs. 59 (29.9)
Aspartate aminotransferase (U/L)  < 40 vs. ≥ 40  179 (89.7) vs. 18 (10.3)
Alanine aminotransferase (U/L)  < 50 vs. ≥ 50 185 (93.9) vs. 12 (6.1)
Calcium (mg/dL)  < 10 vs. ≥ 10  157 (79.7) vs. 40 (20.3)
Timing of metastasis  Concurrent vs. Subsequent    92 (46.7) vs. 105 (53.3)
Number of metastatic sites  < 2 sites vs. ≥ 2 sites  116 (58.9) vs. 81 (41.1)
Lung metastasis Presence vs. Absence  123 (62.4) vs. 74 (37.6)
Bone metastasis Presence vs. Absence    66 (33.5) vs. 131 (66.5)
Brain metastasis Presence vs. Absence    29 (10.3) vs. 253 (89.7)
Liver metastasis Presence vs. Absence     19 (9.6) vs. 178 (90.4)
ECOG-PS, eastern cooperative oncology group performance status.
PATIENTS AND METHODS
The medical records of 368 patients with 
histologically proven metastatic RCC from 8 
university hospitals were retrospectively reviewed. 
The cohort was limited to patients who underwent 
radical nephrectomy and treatment between 1995 
and 2004 with at least 1 cycle of immunotherapy 
[interferon-α, interleukin-2 (IL-2), or a combination 
thereof with or without 5-flourouracil]. Patients 
who received other biologic response modifiers 
and chemotherapeutic regimens were excluded. 
Exclusion criteria also included non-clear cell 
histology, von Hippel-Lindau disease, other 
malignant disease, and followup duration of less 
than 3 mos. A total of 197 patients were eligible 
for this study, with 152 males (77.2%) and 45 
females (22.8%). Interferon-α monotherapy was 
performed in 72 patients, IL-2 monotherapy in 9, 
and combination therapy in 116 patients. The 
mean age was 55.1 ± 11.8 yrs (range, 24 to 83 yrs) 
and the mean survival time was 22.6 ± 20.2 mos 
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Table 2. Univariate Analysis for Disease-Specific Survival
3-yr survival (%) p value*
Gender Male vs. Female 35.3 vs. 35.7 0.318
Age (yrs) < 60 vs. ≥ 60 35.4 vs. 36.4 0.588
Constitutional symptoms Presence vs. Absence 28.9 vs. 40.3 0.035
Local symptoms Presence vs. Absence 31.2 vs. 39.5 0.048
Laterality Right vs. Left vs. Bilateral 32.0 vs. 38.3 0.370
T stage T1 - 3 vs. T4 36.0 vs. 37.5 0.225
Size (cm) < 7 vs. ≧ 7 39.2 vs. 33.5 0.551
Nuclear grade Grade 1 - 3 vs. Grade 4 39.0 vs. 25.6 0.016
Sarcomatoid differentiation Presence vs. Absence 13.9 vs. 38.0 < 0.001
Tumor necrosis Presence vs. Absence 29.1 vs. 39.9 0.082
N stage pNx or pN0 vs. pN1 or pN2 39.0 vs. 20.2 0.003
ECOG-PS 0, 1 vs. 2 - 4 39.7 vs. 14.3 0.003
Hematocrit (%) < 40 vs. ≥ 40 31.9 vs. 43.7 0.106
Platelet count (/mm3) < 450,000 vs. ≥ 450,000 37.8 vs. 17.1 0.003
Alkaline phosphatase (U/L) < 110 vs. ≥ 110 40.6 vs. 24.5 0.036
Aspartate aminotransferase (U/L) < 40 vs. ≥ 40 36.3 vs. 29.1 0.191
Alanine aminotransferase (U/L) < 50 vs. ≥ 50 35.8 vs. 32.1 0.465
Calcium (mg/dL) < 10 vs. ≥ 10 33.6 vs. 45.5 0.381
Timing of metastasis Concurrent vs. Subsequent 33.8 vs. 37.5 0.388
Number of metastatic sites < 2 sites vs. ≥ 2 sites 35.4 vs. 24.8 < 0.001
Lung metastasis Presence vs. Absence 33.4 vs. 39.6 0.283
Bone metastasis Presence vs. Absence 31.9 vs. 37.8 0.217
Brain metastasis Presence vs. Absence 10.1 vs. 38.4 0.121
Liver metastasis Presence vs. Absence 12.3 vs. 38.9 < 0.001
ECOG-PS, eastern cooperative oncology group performance status.
*p value by log-rank test.
(range, 3 to 120 mos). Survival time was defined 
as the time from diagnosis of metastatic disease to 
the date of death or last followup.
The impact of various clinicopathological factors 
on disease-specific survival was investigated. The 
following patient-related, laboratory, tumor-related, 
and metastasis-related features were assessed: 
gender, age, constitutional symptoms at pre-
sentation, local symptoms at presentation, Eastern 
Cooperative Oncology Group Performance Status 
(ECOG-PS) score, commonly used laboratory tests 
(hematocrit, platelet, alkaline phosphatase, aspartate 
aminotransferase, alanine aminotransferase, and 
calcium level), T stage, tumor size, nuclear grade, 
sarcomatoid differentiation, tumor necrosis, N 
stage, timing of metastasis, site of metastatic 
disease (lung, bone, brain, and liver), and number 
of metastatic sites. The clinicopathological infor-
mation of this study cohort is summarized in 
Table 1. 
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Table 3. Multivariate Analysis for Disease-Specific Survival
HR 95% CI p value* Weight
Constitutional symptoms 1.36 0.94 - 1.95 0.099 -
Local symptoms 1.31 0.90 - 1.91 0.153 -
ECOG-PS 1.95 1.22 - 3.12 0.005 0 vs. 1
Platelet count 1.34 0.74 - 2.41 0.333 -
Alkaline phosphatase level 1.24 0.84 - 1.83 0.276 -
N stage 1.94 1.27 - 2.99 0.002 0 vs. 1
Nuclear grade 1.03 0.65 - 1.64 0.899 -
Sarcomatoid differentiation 2.99 1.72 - 5.21 < 0.001 0 vs. 2
Liver metastasis 2.09 1.32 - 3.33 0.002 0 vs. 1
Number of metastatic sites 1.76 1.22 - 2.53 0.003 0 vs. 1
HR, hazard ratio; CI, confidence interval; ECOG-PS, eastern cooperative oncology group performance status score.
*p value by multivariate Cox proportional hazard model.
Kaplan-Meier curves were generated and 
compared by using log-rank test for univariate 
survival analyses. To assess the independent 
impact of clinicopathological factors on disease- 
specific survival, Cox proportional hazards 
regression was used for multivariate survival 
analyses. Based on rounded regression coefficients 
[log hazard ratios (HR) in the final Cox model] of 
variables, the weights of prognostic features were 
determined. A prognostic score was defined as the 
sum of the weights of the independent prognostic 
factors. SPSS for Windows version 12.0 was used 
for statistical analyses. All p values were 2-sided, 
and a p value of less than 0.05 was considered to 
be significant.
RESULTS
Univariate analysis
Of 197 patients, 127 (64.5%) died of cancer at 
last followup, while 2 (1.0%) died of other causes. 
The disease-specific survival rate was 65.4% at 1 
yr, 35.7% at 3 yrs, and 21.8% at 5 yrs. For univariate 
analysis, there was no apparent association 
between survival and gender, age, laterality, T 
stage, tumor size, tumor necrosis, hematocrit level, 
liver enzyme level, serum calcium level, timing of 
metastasis, lung metastasis, bone metastasis or 
brain metastasis (p > 0.05). However, the presence 
of constitutional symptoms (p = 0.035), presence of 
local symptoms (p = 0.048), nuclear grade 4 (p = 
0.016), presence of sarcomatoid differentiation (p < 
0.001), nodal involvement (p = 0.003), ECOG-PS 
score of 2 or greater (p = 0.003), thrombocytosis (p 
= 0.003), increased alkaline phosphatase (p =
0.036), multiple metastatic sites (p < 0.001), and 
presence of liver metastasis (p < 0.001) appeared to 
have a significant influence on survival (Table 2).
Multivariate analysis
Multivariate analysis revealed that the following 
5 features were associated with disease-specific 
survival: sarcomatoid differentiation (presence vs. 
absence, HR = 2.99, p < 0.001), liver metastasis 
(presence vs. absence, HR = 2.09, p = 0.002), ECOG- 
PS (≥ 2 vs < 2, HR = 1.95, p = 0.005), N stage (≥ 
1 vs 0, HR = 1.94, p = 0.002), and number of 
metastatic sites (≥ 2 vs 1, HR = 2.024, p = 0.003) 
(Table 3).
Prognostic stratification model
The weights of independent prognostic factors 
were defined as follows: sarcomatoid differen-
tiation was given a weight of 2, and the remaining 
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Table 4. Disease-Specific Survival Rates by Risk Group
Risk group Cumulative risk score
Patients
(n)
Median time to death 
(mos)
Disease-specific survival rate (%)
1 yr 3 yrs 5 yrs
Low 0  70 44 80.8 55.4 36.0
Intermediate 1 or 2  97 18 66.9 29.2 17.1
High ≥ 3  30  6 24.3 0.0 0.0
Total 197 20 65.4 35.7 21.8
Fig. 1. Disease-specific survival curves according to risk scores (A) and risk groups (B). p value = 0.001 between low 
risk and intermediate risk, p value < 0.001 between intermediate risk and high risk.
4 factors were assigned a weight of 1 (Table 4).
An individual prognostic score was defined as 
the sum of the weights of these factors. The 
prognostic scores were 0 in 70 patients, 1 in 55, 
2 in 42, 3 in 17, 4 in 9, and 5 in 4. Survival curves 
showed a statistically significant difference between 
those with scores 0 and 1 (p = 0.038) and scores 2 
and 3 (p = 0.039). However, there was no differ-
ence between those with scores 1 and 2 (p = 0.052), 
3 and 4 (p = 0.061), and 4 and 5 (p = 0.618) (Fig. 1).
As a consequence, the cohort was subdivided 
into 3 groups as follows: a low risk group (score 
0), intermediate risk group (score 1 or 2), and high 
risk group (score 3 or greater) (Fig. 1), each of 
which had disease-specific survival rates that are 
shown in Table 4.
DISCUSSION
Investigators have concentrated on the prognostic 
stratification of patients with advanced or 
metastatic RCC for years, and a number of RCC 
outcome prediction models have previously been 
reported.6-12 Zisman et al. reported a single 
predictive system of patients with and without 
metastatic RCC, the University of California Los 
Angeles Integrated Staging System (UISS), which 
is based on 661 patients and incorporates TNM 
pathologic stage, ECOG-PS, and Fuhrman grade 
to predict overall survival after patients undergo 
radical nephrectomy. Frank et al.13 proposed the 
stage, size, nuclear grade, and necrosis (SSIGN) 
score, which is based on 1801 patients with clear 
cell RCC treated by radical nephrectomy. The 
SSIGN score stratifies the risk of death from RCC 
based on these features.
Recently, prognostic prediction systems have 
focused only on metastatic RCC.6-10 Motzer et al.10 
suggested the prognostic stratification of 670 
patients with advanced RCC. In their study, 5 
prognostic factors (Karnofsky performance status, 
A B
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serum lactate dehydrogenase, hemoglobin, corrected 
serum calcium, and prior nephrectomy) were 
identified and used to categorize patients with 
metastatic RCC into 3 risk groups. They also 
reviewed 463 patients who were treated with 
interferon-α for metastatic RCC and developed 
another algorithm that consists of Karnofsky 
performance status, lactate dehydrogenase, 
hemoglobin, corrected serum calcium, and time 
from diagnosis to immunotherapy.9 Leivobich et 
al.8 proposed the first predictive algorithm in 
patients with metastatic RCC after nephrectomy 
and IL-2-based immunotherapy. In their model, 
regional lymph node status, constitutional 
symptoms, location of metastases, sarcomatoid 
histology, and thyroid stimulating hormone (TSH) 
levels were associated with survival. Atzpodien et 
al.6 demonstrated a comprehensive prognostic 
system of pretreatment clinical parameters in 
patients with metastatic RCC treated with 
different subcutaneous recombinant cytokine-based 
home therapies in consecutive trials. Six parameters 
(neutrophil counts, lactate dehydrogenase, C- 
reactive protein, time from diagnosis of tumor to 
metastatic disease, number of metastatic sites, and 
bone metastasis) were identified as independent 
prognostic factors.
In our study, 24 clinicopathological features 
were evaluated for their impacts on survival of 
patients with metastatic RCC who were treated 
with nephrectomy and immunotherapy. Sub-
sequently, a new comprehensive prognostic 
model was devised that consisted of 3 risk groups. 
The study data showed various median survival 
times according to each risk group ranging from 
6 mos in the high-risk group to 44 mos in the low- 
risk group. This scoring system was determined 
by the weighted sum of 5 features (sarcomatoid 
differentiation, liver metastasis, ECOG-PS, N 
stage, and number of metastatic sites). The weight 
of each variable was considered and only 
sarcomatoid differentiation was given a weight of 
2 because of its strong prognostic impact (HR = 
2.99). The relatively strong impact of sarcomatoid 
differentiation has also been identified in previous 
reports.8,11
Generally, extrapulmonary metastasis has been 
regarded as an independent prognostic factor in 
metastatic RCC patients.7,8,14,15 In this study, only 
hepatic involvement showed a significant influence 
on survival whereas brain and bone involvement 
did not. Although the cut-off value to define 
multiplicity of metastatic sites has been inconsistent, 
many authors have emphasized the significance of 
the number of metastatic sites in these patients. 
6,7,16-18 Performance status was established as an 
important prognostic factor without any uncer-
tainty,9,10,16-19 suggesting a prognostic significance 
for regional node involvement similar to the work 
of Leibovich et al. However, it is not certain 
whether regional nodal involvement is a feasible 
prognostic factor in any metastatic RCC patients 
since both this study and those of Leibovich et al. 
are restricted to patients who underwent 
nephrectomy and immunotherapy.
The present study was limited to patients with 
clear cell RCC since the histological subtype is 
associated with the biologic aggressiveness of 
RCC.20 To eliminate possible confounding factors, 
the study cohort was limited to patients with 
metastatic RCC who were treated with nephrectomy 
and immunotherapy. Nevertheless, the study still 
showed some limitations as well as the general 
limitations of a retrospective study, where 
immunotherapy protocol and number of cycles 
were not identical, and this difference was not 
considered in the data analysis. However, 
systemic immunotherapy demonstrated a minimal 
impact on outcome in advanced RCC, suggesting 
that the difference did not cause a significant bias 
in developing this prognostic model. 
The objectives of this study were to develop a 
reliable prognostic model based on features 
readily available to clinicians and pathologists. 
There are no other ancillary tests such as erythrocyte 
sedimentation rate, thyroid stimulating hormone, 
C-reactive protein, and lactate dehydrogenase that 
have previously been studied and identified as 
useful in the management of patients with RCC.6, 
8-10,14,15 For this reason, the clinical feasibility of 
this model is expected to be greater in common 
clinical settings. Recently, race has been shown to 
be a significant predictor of overall survival 
within a clinical trial patient population with 
RCC, even in those with metastatic RCC.21,22 
However, there was no literature in English about 
a predictive model for patients treated with 
nephrectomy and immunotherapy based on Asian 
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populations including Koreans. Therefore, the 
prognostic model described herein can be used to 
predict survival and stratify patients for prospective 
clinical trials although further validation of the 
model through prospectively designed clinical 
trials is needed. 
In summary, sarcomatoid differentiation, liver 
metastasis, ECOG-PS, N stage, and number of 
metastatic sites were found to be independently 
associated with survival of patients with metastatic 
RCC who were treated with nephrectomy and 
immunotherapy. Based on these features, a 
comprehensive prognostic stratification model 
was developed to predict survival and stratify 
patients for prospective clinical trials.
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